News Breaks |
|
|
| January 2, 2013 |
| 10:25 EDT |  | MYL | Mylan receives final approval from FDA for ANDA for generic Maxalt MLT tablets
Mylan announced that its subsidiary Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Applications for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg, and Rizatriptan Benzoate Tablets, 5 mg and 10 mg. These products are the generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults. |
|
|
News For MYL From The Last 14 Days Check below for free stories on MYL the last two weeks. |
|
|
| May 21, 2013 |
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
 Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | MYL | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
| |
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | MYL | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| May 9, 2013 |
| 16:34 EDT | | MYL | Mylan initiated with an Underperform at BMO Capital
Subscribe for More Information |
|
|
|
|
|
